Heart check: do Nerve-Targeting drugs also shield the heart in rare amyloidosis?

NCT ID NCT05873868

Ongoing Knowledge-focused Sponsor: Rennes University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 20 adults with hereditary transthyretin amyloidosis (ATTRv) who have both nerve and heart involvement. They are treated with patisiran or vutrisiran for two years. Researchers use MRI scans and questionnaires to see how the drugs affect heart structure and function.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: patisiran or vutrisiran
What this could lead to: If successful, this could clarify whether these drugs protect the heart in mixed-form ATTRv amyloidosis, guiding future treatment decisions.
What could go wrong: This is a small observational study (20 people) with no control group, so results may not prove cause and effect or apply broadly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AMYLOIDOSIS, HEREDITARY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

familial amyloid neuropathy hereditary amyloidosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AMYLOIDOSIS, HEREDITARY TRANSTHYRETIN AMYLOIDOSIS

Contacts and locations

Locations

APHP Henri Mondor

Créteil, France
CHU Bordeaux Haut-Levêque

Bordeaux, France
CHU Grenoble Alpes

Grenoble, France
CHU Nancy Institut Louis Mathieu

Nancy, France
CHU Rangueil Toulouse

Toulouse, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.